Current and future use of dipyridamole in patients with COVID-19
Current use of dipyridamole in COVID-19 is mainly based on its antithrombotic activity, since there is no robust clinical effectiveness data. The decision to use dipyridamole in COVID-19 should be individualized, considering the experimental nature of this treatment.
Saved in:
Main Authors: | I. S. Burashnikova (Author), V. M. Tsvetov (Author), K. B. Mirzaev (Author), D. A. Sychev (Author) |
---|---|
Format: | Book |
Published: |
Izdatelstvo OKI,
2020-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Current and future use of remdesivir in patients with COVID-19
by: V. M. Tsvetov, et al.
Published: (2020) -
Current and future use of aminodihydrophthalazindione sodium in patients with COVID-19, including for «cytokine storm» therapy
by: V. M. Tsvetov, et al.
Published: (2020) -
Current and future use of umifenovir in patients with COVID-19
by: Yu. Yu. Kiselev, et al.
Published: (2020) -
Is it possible to use riamilovir to prevent infection and treat COVID-19?
by: V. M. Tsvetov, et al.
Published: (2020) -
Current and future use of vitamin D<sub>3</sub> in patients with COVID-19
by: I. N. Sychev, et al.
Published: (2020)